Catalyst Dossier · compiled by CeliA 🧫

Alnylam Pharmaceuticals, Inc. (ALNY)

Pharmaceutical Preparations · market cap $36.9B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alnylam Pharmaceuticals (ALNY) is a Cambridge-based RNAi therapeutics pioneer with an approved commercial product (Amvuttra for hATTR amyloidosis), a late-stage pipeline anchored by vutrisiran and nucresiran in ATTR cardiomyopathy, and a diversified Phase 2/3 portfolio spanning hypertension (zilebesiran), obesity (ALN-2232, ALN-4324), Alzheimer's (ALN-APP), and rare diseases. The company turned profitable in 2025 with $3.71B in revenue and $314M net income after years of deep losses, marking a meaningful commercial inflection.

The catalyst path

2026-07-30Earningsimp 5/10
2027-04-27 (est.)Phase 2 · ALN-2232imp 7/10

Pipeline

Asset	Phase	Indication
Amvuttra	Approved	hATTR Amyloidosis
ALN-APP	Phase 2	Alzheimer Disease
Vutrisiran	Phase 3	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
ALN-2232	Phase 2	Obesity
ALN-AGT01 RVR	Phase 2	Hypertension
ALN-CC5	Phase 2	Paroxysmal Nocturnal Hemoglobinuria (PNH)
Lumasiran	Phase 3	PH1
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion	Phase 2	TTR-mediated Amyloidosis
ALN-4324	Phase 2	Obese or Overweight Healthy Volunteers
ALN-TTRSC (revusiran) for subcutaneous administration	Phase 2	TTR-mediated Amyloidosis
Zilebesiran	Phase 3	Hypertension
ALN-RSV01	Phase 2	Respiratory Syncytial Virus Infections
Nucresiran	Phase 3	Transthyretin Amyloidosis With Cardiomyopathy
patisiran (ALN-TTR02)	Phase 3	TTR-mediated Amyloidosis
ALN-AGT01	Phase 2	Hypertension
Givosiran	Phase 3	Acute Hepatic Porphyria
Patisiran	Phase 3	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
ALN-6400	Phase 2	Hereditary Hemorrhagic Telangiectasia
Revusiran (ALN-TTRSC)	Phase 3	TTR-mediated Amyloidosis
Revusiran	Phase 2	Transthyretin (TTR)-Mediated Amyloidosis

Price & technical context

3-month

-8.8%

6-month

-24.4%

12-month

-8.5%

52-wk range

$278.09–$491.22

vs 50-day MA

+2.0%

vs 200-day MA

-17.9%

Realized vol

36.5%

Max drawdown

-43.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALNY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.